Company Overview
Molina Healthcare, Inc. operates as a provider of managed healthcare services specifically designed for low-income families and individuals participating in Medicaid, Medicare, and state insurance marketplace programs across the United States. The company functions within the broader Healthcare sector and the specialized Healthcare Plans industry, positioning itself as a critical entity in the public and private payer landscape. Molina Healthcare, Inc. currently maintains a market capitalization of $7.32B and reports a trailing twelve-month revenue of $43.56B, employing approximately 19,000 individuals to deliver its services. These valuation and revenue metrics indicate that the company represents a significant mid-cap player with substantial operational scale, allowing it to negotiate favorable terms with providers and manage complex regulatory environments inherent to government-funded healthcare programs.
Financial Health
The company reports a trailing twelve-month revenue of $43.56B, generating net income of $472.00M and an EBITDA of $902.00M, revealing a significant gap between top-line revenue and bottom-line profit that highlights a cost structure dominated by high operating expenses and regulatory costs. This disparity suggests that while the volume of services provided is massive, the margin available to cover fixed costs and generate pure profit is relatively constrained by the nature of the managed care model. Free cash flow stands at -$100,000,000, indicating that current capital expenditures and working capital requirements exceed operating cash generation, which limits immediate financial flexibility for aggressive expansion or large-scale share repurchases without external financing. The gross margin is 9.4%, while the operating margin is -1.5%, and the profit margin is 1.1%, illustrating that the company operates with thin profitability where operating expenses nearly consume the entire gross profit before reaching a modest net income. On the balance sheet, Molina holds $8.26B in cash against $4.05B in debt, resulting in a debt-to-equity ratio of 99.44, which presents a leveraged profile where cash reserves provide a substantial buffer against interest obligations despite the high leverage. The current ratio is 1.69, indicating a conservative short-term liquidity position where current assets are well in excess of current liabilities, ensuring the ability to meet immediate financial obligations. Return on Equity is 11.0% and Return on Assets is 3.1%, metrics that reveal management effectiveness in generating shareholder value relative to equity invested and utilizing the total asset base, respectively.
Valuation Assessment
The trailing twelve-month P/E ratio is 15.94, while the forward P/E is 16.42, implying that the market expects a modest deceleration in earnings growth or a slight increase in valuation multiple relative to current performance. The price-to-book ratio stands at 1.78, indicating that the market values the company at a premium of 78% over its net asset book value, reflecting confidence in the brand and regulatory franchise. The price-to-sales ratio is 0.17, and the EV/EBITDA is 3.45, suggesting that the stock is valued at a fraction of its sales revenue and on a very low multiple of earnings before interest, taxes, and depreciation, which is typical for capital-intensive healthcare plans with high debt loads. The 52-week high is $359.97 and the 52-week low is $121.06, placing the current valuation within a wide historical range that underscores significant price volatility over the past year. The beta is 0.50, indicating that the stock price exhibits low volatility relative to the broader market, moving with half the intensity of the overall market index.
Growth & Income
Revenue growth year-over-year is 7.1%, while earnings growth year-over-year is N/A, meaning that earnings performance cannot be compared to the revenue trajectory based on available data. For non-dividend payers, the company reinvests earnings into growth rather than distributing cash to shareholders, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. The absence of a dividend payout allows the firm to retain capital for operational needs, debt reduction, or future acquisitions, though this forgoes regular income for income-seeking investors. The overall growth and income profile is characterized by double-digit revenue expansion in a regulated sector, coupled with a lack of dividend support and reliance on internal capital generation and cash reserves to fund operations.